Application of farnesol in preparation of medicine for treating intestinal adenoma
By using aceta alcohol to inhibit the Wnt/β-catenin signaling pathway, the existing intestinal adenoma treatment methods are solved, effective treatment of intestinal adenomas is achieved, and the size and number of intestinal adenomas are reduced.
Patent Information
- Application Number
- CN202410986572.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-23
- Publication Date
- 2024-11-08
- Estimated Expiration
- Not applicable · inactive patent
Smart Images

Figure BDA0004957579000000021 
Figure BDA0004957579000000042 
Figure BDA0004957579000000052
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of new drug applications, and particularly relates to application of farnesol in preparing drugs for treating intestinal adenoma. Background Art
[0002] Intestinal adenoma is a common intestinal disease, which refers to a benign tumor formed in the intestine. It mainly occurs in the colon and rectum and is formed by abnormal proliferation of cells on the intestinal mucosa. At present, the cause of intestinal adenoma is not fully understood, but studies have shown that it is related to dietary structure and lifestyle habits. High-fat, high-protein, low-fiber dietary habits, as well as long-term smoking and drinking, may increase the risk of intestinal adenoma. Genetic factors are also considered to be one of the important influencing factors of intestinal adenoma, and people with a family history of the disease are at a higher risk of disease. The symptoms of intestinal adenoma are usually not obvious, especially in the early stages. Some patients may experience non-specific symptoms such as abdominal pain, bloating, constipation or diarrhea. When the intestinal adenoma is large or malignant, symptoms such as anemia, weight loss, and abdominal mass may occur. Intestinal adenoma may also cause changes in bowel habits, such as thinner stools, increased bowel movements, and blood in the stool.
[0003] The treatment of intestinal adenomas is mainly surgical, and the appropriate surgical method is selected according to the size of the adenoma and the risk of malignant transformation. For small intestinal adenomas discovered early, they can be treated through endoscopic resection or minimally invasive surgery. For larger intestinal adenomas or those with a tendency to malignant transformation, laparotomy may be required for resection. In addition to surgical treatment, chemotherapy, targeted therapy and other methods can also be considered for auxiliary treatment. Therefore, various treatment methods are somewhat traumatic and have large side effects.
[0004] Farnesol is naturally present in essential oils such as lemongrass oil and citronella oil. It has a unique green lily of the valley aroma, as well as green and woody notes, and can be used as a blending ingredient for floral fragrances. However, no research has been found to show that farnesol can treat intestinal adenomas. Summary of the invention
[0005] Purpose of the invention: In order to solve the defects of the prior art, the present invention provides the use of farnesol in the preparation of drugs for treating intestinal adenomas.
[0006] Technical solution: In order to achieve the above-mentioned invention object, the present invention adopts the following technical solution:
[0007] In a first aspect, the present invention provides the use of farnesol in preparing a drug for treating intestinal adenoma.
[0008] As a specific embodiment, the farnesol is used as the sole active ingredient in the preparation of a drug for treating intestinal adenoma.
[0009] As a specific implementation scheme, the dosage of farnesol is 100-500 mg / kg.
[0010] As a specific implementation scheme, the drug for treating intestinal adenoma is an oral drug or an injectable drug.
[0011] In a second aspect, the present invention provides the use of farnesol in preparing a Wnt / β-catenin signaling pathway inhibitor.
[0012] In a third aspect, the present invention provides use of a composition comprising farnesol in the preparation of a medicament for treating intestinal adenoma.
[0013] As a specific embodiment, in the composition, farnesol is the only active ingredient.
[0014] As a specific implementation scheme, the dosage of farnesol is 100-500 mg / kg.
[0015] As a specific embodiment, the composition comprises farnesol and pharmaceutically acceptable excipients.
[0016] As a specific embodiment, the dosage form of the composition is selected from tablets, capsules, powders, granules, oral liquids or injections.
[0017] In a fourth aspect, the present invention provides use of a composition comprising farnesol in the preparation of a Wnt / β-catenin signaling pathway inhibitor.
[0018] The farnesol described in the present invention has a molecular formula of C 15 H 26 O, chemical structure is as follows:
[0019]
[0020] Beneficial effects: Compared with the prior art, the present invention is the first to find that farnesol can effectively treat intestinal adenomas. Experimental studies have confirmed that farnesol can effectively inhibit the size and number of intestinal adenomas, reduce the expression levels of β-catenin, cylinD1 and c-Myc proteins in colorectal tissues, and effectively treat intestinal adenomas by inhibiting the Wnt / β-catenin signaling pathway. Therefore, farnesol can be used to treat intestinal adenomas and is worthy of further promotion and application. DETAILED DESCRIPTION
[0021] The technical scheme in the embodiments of the present invention will be described clearly and completely below. If the specific conditions are not specified in the embodiments, the conventional conditions or the conditions recommended by the manufacturer are followed. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.
[0022] Example
[0023] 1. Main experimental materials
[0024] Preparation of 2% dextran sulfate sodium salt (9011-18-1, relative molecular mass: 36000-50000, MP Biomedicals, USA): First prepare 1L of deionized water, sterilize it in an autoclave and cool it to room temperature, add 20g of dextran sulfate sodium powder on a clean bench, and stir it evenly with a magnetic stirrer.
[0025] Farnesol (99%, Shanghai Tongtian Biotechnology Co., Ltd.).
[0026] beta-catenin antibody, c-Myc antibody, cyclin DI antibody, abcam, USA.
[0027] 36 4-week-old SPF-grade APC (min / +) mice weighing 16-20 g were identified by tail docking. They were housed in separate cages under air conditioning, and the bedding was changed 2-3 times a week. The drinking water bottles, mouse cages, bedding, gavage needles and other consumables used for feeding and gavage required high-pressure steam sterilization. This experiment strictly complies with the relevant provisions of the national laboratory animal welfare ethics.
[0028] 2. Experimental methods
[0029] 2.1 Grouping, modeling and drug administration
[0030] The mice were randomly divided into 6 groups by random number method, namely blank group, model group, aspirin group, farnesol low-dose group, farnesol medium-dose group and farnesol high-dose group, with 6 mice in each group. Blank group: normal drinking water and food were given. Model group: drinking water containing 2% dextran sulfate sodium (DSS) was freely available for one week, and then 0.3 ml of distilled water was gavaged daily. Aspirin group: drinking water containing 2% dextran sulfate sodium (DSS) was freely available for one week, and then 0.3 ml of aspirin suspension was gavaged daily. Farnesol low-dose group: drinking water containing 2% dextran sulfate sodium (DSS) was freely available for one week, and then low-dose farnesol (100 mg / kg) was gavaged daily. Farnesol medium-dose group: drinking water containing 2% dextran sulfate sodium (DSS) was freely available for one week, and then medium-dose farnesol (300 mg / kg) was gavaged daily. Farnesol high-dose group: Drinking water containing 2% sodium dextran sulfate (DSS) was freely available for one week, and then high-dose farnesol was gavaged daily (500 mg / kg). After 24 hours of water deprivation at the end of the 12th week of administration, the mice were killed by dislocation, and the colorectal tissues of the mice in each group were dissected to observe the formation of macroscopic adenomas. The number and size of macroscopic adenomas in the intestines of the mice in each group were counted, and they were divided into >2mm, 1-2mm and <1mm according to the diameter of the adenoma. The colorectal tissue was cut into 0.5×0.5cm size, and part of it was immersed in formaldehyde fixative. The next day, the fixed colorectal tissue was dehydrated by gradient, embedded in paraffin, routinely sliced and HE stained, etc. The other part was placed in an EP tube and quickly frozen in liquid nitrogen, stored in a -80℃ refrigerator for later experiments. Adenoma specimens from various parts of the intestine were retained for immunohistochemical detection.
[0031] 2.2 Evaluation of the effectiveness of intervention on intestinal adenoma growth in mice
[0032] The weight of mice in each group was measured daily, and the changes in the quality of mice during the experiment (mental state, mouse hair, activity, appetite, feces) were observed and counted. The number and location of adenomas were recorded and their sizes were measured, and they were divided into >2mm, 1-2mm and <1mm according to the diameter.
[0033] 2.3 Immunohistochemistry to determine the expression levels of β-catenin, c-Myc, and cyclinD1 proteins in mouse colorectal tissue
[0034] β-catenin is located on the cell membrane, c-Myc is stained for the cytoplasm, and cyclinD1 is located in the nucleus. The positive standard is that the stained cell part is brown or brown. Observe each slice and randomly select 5 fields of view to take pictures. Use the Image-ProPlus6.0 professional image analysis system to analyze the pictures, and obtain the integral optical density IOD and positive area Area of the selected positive area. After summarizing the data, calculate the average optical density MOD (ie IOD / Area) of the corresponding positive expression. Paraffin sections are operated strictly according to the steps in the immunohistochemistry instructions. The steps are as follows:
[0035] A. Paraffin sections (same process as above) were dewaxed in xylene solution, dehydrated with anhydrous and 95% ethanol, placed in a stainless steel tank, added with sodium citrate antigen repair solution and boiled under high pressure for repair.
[0036] B. Place the slides into the corresponding immunohistochemistry kits in order, rinse thoroughly with TBST and then block. After reacting at room temperature at 25 degrees for 1 hour, add the primary antibody to fully infiltrate and incubate in a refrigerator at 4°C overnight.
[0037] C. Take out the immunohistochemistry kit and let it stand at room temperature for 30 minutes. Wash off the primary antibody with TBST buffer and add the secondary antibody, and let it stand at room temperature for 1 hour.
[0038] D. After washing away the secondary antibody with TBST, add DAB color developing solution and observe under a microscope until the tissue reaction turns brown or tan.
[0039] E. Rinse with running water to remove the DAB color developing solution. After counterstaining with hematoxylin for 60 seconds, rinse with warm running water until the sample turns blue.
[0040] F. After gradient dehydration with 95% and anhydrous ethanol, soak in xylene until transparent, seal with neutral resin and mark the groups.
[0041] G. Observe and take pictures under a microscope, and perform statistical analysis on the immunohistochemistry of each group.
[0042] 2.4 Statistical analysis
[0043] SPSS26.0 was used to analyze the data, and analysis of variance (ANOVA) and post hoc least significant difference (LSD) were used to compare the differences between the groups. Data were expressed as mean ± standard deviation (SD); P < 0.05 was considered statistically significant.
[0044] 3. Results
[0045] 3.1 Effects of farnesol on the size and number of adenomas in mice
[0046] The number and size of macroscopic adenomas in the intestines of each group of mice were statistically analyzed. The results are shown in Table 1 below.
[0047] Table 1 Effect of farnesol on the number and size of intestinal adenoma tissues ( n=6)
[0048]
[0049] Note: Compared with the blank group, # P<0.05; compared with the model group, *P<0.05.
[0050] As shown in Table 1 above, only a small number of adenomas were found in the colorectum of the blank group mice, with smooth surfaces, slightly protruding from the intestinal mucosal surface, and none >2 mm. Compared with the blank group, the number of adenomas in each diameter range and the total number of adenomas in the model group mice increased significantly, indicating that the model was successful. Compared with the model group, the total number of adenomas and the number of adenomas >2 mm in the aspirin group, the low-dose farnesol group, the medium-dose farnesol group and the high-dose farnesol group were significantly reduced. Compared with the model group, the number of adenomas in each diameter range in the high-dose farnesol group was significantly reduced, which was basically equivalent to the effect of the positive drug aspirin group. The above results show that farnesol can effectively reduce the number and size of adenomas in mice with intestinal adenomas.
[0051] 3.2 Effect of farnesol on the expression levels of β-catenin, cylin D1 and c-Myc proteins in mouse colorectal tissue
[0052] The Wnt signaling pathway can affect the growth and viability of cancer cells and plays a leading role in the initiation and progression of the multi-stage carcinogenesis of the intestine. β-catenin, c-Myc, and cylin D1 are related proteins of the Wnt signaling pathway. The Wnt protein binds to the surface receptor of the specific receptor Frizzled protein, and then activates the GSK3 signaling pathway, causing GSK3 to bind to β-Catenin, hindering the degradation of β-Catenin, and promoting the stemness, proliferation, or tumor formation of cells. The expression levels of β-catenin, cylin D1, and c-Myc proteins in the colorectal tissues of each group of mice in the present invention were statistically analyzed, and the results are shown in Table 2 below.
[0053] Table 2 Effects of farnesol on the expression levels (MOD values) of β-catenin, cylin D1 and c-Myc proteins n=6)
[0054]
[0055] Note: Compared with the blank group, # P<0.05; compared with the model group, *P<0.05.
[0056] From the results in Table 2 above, it can be seen that compared with the blank group, the expression levels of β-catenin, cylin D1 and c-Myc proteins in the colorectal tissues of mice in the model group were significantly increased. Compared with the model group, there was no significant difference in the expression levels of β-catenin, cylin D1 and c-Myc proteins in the colorectal tissues of mice in the low-dose farnesol group. Compared with the model group, the expression levels of β-catenin, cylin D1 and c-Myc proteins in the colorectal tissues of mice in the aspirin group, the medium-dose farnesol group and the high-dose farnesol group were significantly reduced. The above results show that farnesol can significantly reduce the expression levels of β-catenin, cylin D1 and c-Myc proteins in the colorectal tissues of mice with intestinal adenoma, which is related to its inhibitory effect on the Wnt / B-catenin signaling pathway abnormally activated by APC mutation. Therefore, farnesol can be used to treat intestinal adenomas.
[0057] The above-mentioned embodiments only express several implementation methods of the present invention, and the descriptions thereof are relatively specific and detailed, but they cannot be understood as limiting the scope of the invention patent. It should be pointed out that, for ordinary technicians in this field, several variations and improvements can be made without departing from the concept of the present invention, and these all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be subject to the attached claims.
Claims
1. Application of farnesol in the preparation of drugs for treating intestinal adenoma.
2. The use according to claim 1, characterized in that: The farnesol is used as the sole active ingredient in the preparation of a drug for treating intestinal adenoma.
3. The use according to claim 1, characterized in that: The drug for treating intestinal adenoma is an oral drug or an injectable drug.
4. Application of farnesol in the preparation of Wnt / β-catenin signaling pathway inhibitors.
5. Use of a composition comprising farnesol in the preparation of a drug for treating intestinal adenoma.
6. The use according to claim 5, characterized in that: In the composition, farnesol is the only active ingredient.
7. The use according to claim 5, characterized in that: The composition comprises farnesol and pharmaceutically acceptable excipients.
8. The use according to claim 5, characterized in that: The dosage form of the composition is selected from tablets, capsules, powders, granules, oral liquids or injections.
9. Use of a composition comprising farnesol in the preparation of a Wnt / β-catenin signaling pathway inhibitor.
